Mari Gilljam

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Journal article: CYTOTHERAPY. 2023;25(6):s13-s14
13 Tissue Engineering: GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hållstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s41-s41a
P-010: Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Article: CELL REPORTS MEDICINE. 2022;3(2):100508
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist P-H; Walther-Jallow L; Mellstrom K; Liwing J; Gustafsson C; Mansson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren H-G; Alici E
Article: CANCERS. 2019;11(1):E69-69
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Chrobok M; Dahlberg CIM; Sayitoglu EC; Beljanski V; Nahi H; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Article: HUMAN GENE THERAPY. 2012;23(10):1090-1100
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Article: CYTOTHERAPY. 2010;12(8):1044-1055
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Article: IMMUNOTHERAPY. 2009;1(5):753-764
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Bjorkstrom NK; Soderdahl G; Cederlund K; Kimby E; Aschan J; Ringden O; Ljunggren H-G; Dilber MS
Article: BLOOD. 2008;111(6):3155-3162
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici E; Sutlu T; Boejrkstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Article: LEUKEMIA. 2003;17(10):1973-1980
Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Article: HUMAN IMMUNOLOGY. 2001;62(10):1092-1098
A new method for in vitro expansion of cytotoxic human CD3^-CD56⁺ natural killer cells
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2000;28(10):1137-1146
Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution.
Carlens S; Gilljam M; Remberger M; Aschan J; Christensson B; Dilber MS
Article: JOURNAL OF MEDICAL VIROLOGY. 1997;53(1):51-59
Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: Evidence of highly cross-neutralizing antibody responses in early patient sera
Lundkvist A; Hukic M; Horling J; Gilljam M; Nichol S; Niklasson B
Article: JOURNAL OF GENERAL VIROLOGY. 1996;77 ( Pt 12):3063-3067
Isolation and characterization of Tula virus, a distinct serotype in the genus Hantavirus, family Bunyaviridae.
Vapalahti O; Lundkvist A; Kukkonen SK; Cheng Y; Gilljam M; Kanerva M; Manni T; Pejcoch M; Niemimaa J; Kaikusalo A; Henttonen H; Vaheri A; Plyusnin A

Alla övriga publikationer

Conference publication: CYTOTHERAPY. 2023;25(6):S13-S14
GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hallstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s46-s47
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S46-S47
PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S41
Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Meeting abstract: BLOOD. 2021;138:4796
CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
Nahi H; Chrobook M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Walther-Jallow L; Liwing J; Klimkowska M; Gahrton G; Ljungman P; Ljunggren H-G; Alici E
Conference publication: BLOOD. 2019;134:1848
Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
Karvouni M; Zhou H; Kathleen A; Ma Q; Baloch AH; Zhu T; Zhang H; Gilljam M; Lundqvist A; Kaufmann GF; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E163-E164
A novel antiCD38-CAR construct increases the in vitro responsiveness of NK cells against Multiple Myeloma cells
Karvouni M; Wagner AK; Baloch AH; Gilljam M; Lundqvist A; Alici E
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):348
Optimized genetic modification of primary human NK cells
Wagner AK; Chrobok M; Hussain A; Gilljam M; Dahlberg CIM; Sutlu T; Duru AD; Nahi H; Lundqvist A; Ljunggren H-G; Alici E
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):342
Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu
Chrobok M; Dahlberg CIM; Sayitoglu C; Nahi H; Sarhan D; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Conference publication: HUMAN GENE THERAPY. 2012;23(10):A151
Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Conference publication: HUMAN GENE THERAPY. 2008;19(10):1183
Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma
Alici E; Sutlu T; Bjokstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Conference publication: BLOOD. 2002;100(11):595A
Derivation of expanded killer cells from patients with B-chronic lymphocytic leukemia (B-CLL): A potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI